Immune-Boosting Antibody Combination Could Improve Lymphoma Survival

From Drug Discovery Today - November 30, 2017

Researchers from the University of Southampton tested different combinations of antibodies* in the lab to see how they interact with each other and what effect this has on how the immune system fights cancer.

They found one combinationanti-CD27 and anti-CD20greatly increased life expectancy in mice with cancer. While most of the mice given just one of the antibodies died within 80 days, nearly all mice given both antibodies survived beyond 100 days.

When combined, the researchers found the antibodies recruit greater numbers of immune cells called myeloid cells, as well as increasing their ability to destroy cancer cells.

As a direct result of this study, the combination will now be tested in patients as part of a clinical trial funded by Cancer Research UK.

Continue reading at Drug Discovery Today »